Evidence map›Paper›PMID 38667772›Full record

ReviewMarine drugs2024

Marine Natural Products Rescuing the Eye: A Narrative Review.

Filippo Lixi, Livio Vitiello, Giuseppe Giannaccare

Open access · goldAbstract readReview
In one paragraph

Review in Marine drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Protective Effects ofJournal of microbiology and biotechnology · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Filippo LixiEye Clinic, Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy.ORCID 0009-0008-0956-4925
Livio VitielloEye Unit, "Luigi Curto" Hospital, Azienda Sanitaria Locale Salerno, 84035 Polla, Italy.ORCID 0000-0001-7867-3342
Giuseppe GiannaccareEye Clinic, Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy.ORCID 0000-0003-2617-0289
University of Cagliari · ITASL Roma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Different degrees of visual impairment lead to a decrease in patient wellbeing, which has an adverse effect on many facets of social and professional life. Eye disorders can affect several parts of the eye, most notably the retina and the cornea, and the impacted areas might share a common form of cellular damage or dysfunction (such as inflammation, oxidative stress and neuronal degeneration). Considering that marine organisms inhabit a broad variety of marine habitats, they display a great degree of chemical diversity. As a result, molecules with a marine origin are receiving more and more attention in the hopes of developing novel therapeutic approaches. For instance, fucoxanthin has been demonstrated to be effective in protecting the retina against photo-induced damage, while largazole, astaxanthin and spirulina have all shown antioxidant, anti-inflammatory and antiapoptotic activities that can be useful for the management of several ocular diseases, such as age-related macular degeneration and ocular surface disorders. The aim of this review is to analyze the scientific literature relating to the therapeutic effects on the eye of the main natural marine products, focusing on their mechanism of action and potential clinical uses for the management of ocular diseases.

Indexed as

Aquatic OrganismsBiological ProductsEye DiseasesAnimalsAntioxidantsHumansAntioxidantsBiological ProductsAMDdry eye diseaseeyeglaucomamarine natural products

Identifiers

PMID38667772
PMCPMC11050997
OpenAlexW4393279037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.